Last updated: February 14, 2026
Overview
NDC 00054-3553 corresponds to Clofazimine (marketed as Lamprene), an antimycobacterial agent primarily used in the treatment of leprosy and off-label for certain multidrug-resistant tuberculosis (MDR-TB) cases. Its niche status, manufacturing pipeline, regulatory environment, and competitive landscape shape its market dynamic and pricing potential.
Market Size and Demand
Leprosy Treatment Market
- Global leprosy prevalence peaked in the 1980s with approximately 5.6 million cases.
- Current estimates report about 200,000 new cases annually, mostly in India, Brazil, and Indonesia.
- Clofazimine is part of multicomponent regimens: typically combined with rifampicin and dapsone.
Off-Label Use for MDR-TB
- Growing use as adjunct therapy in multidrug-resistant tuberculosis.
- World Health Organization (WHO) inclusion in MDR-TB regimens since 2019.
- Off-label demand varies, with limited formal supply channels.
Market Size Estimation
| Region |
Estimated Annual Cases |
Potential Demand (kg)* |
Notes |
| India |
120,000+ |
50-100 |
Largest endemic zone |
| Brazil |
20,000+ |
8-15 |
Regional demand |
| Global (excluding endemic zones) |
60,000+ |
25-50 |
Off-label off-patent use |
*Assuming an average dose of 50 mg daily, leading to annual consumption estimates.
Manufacturing and Supply Dynamics
- Originated from Johnson & Johnson's Icagen business unit.
- Present manufacturers include Nichermed and other generic producers.
- Patent status: Off-patent, leading to multiple generic options.
- Supply chain disruptions are minimal but dependent on demand spikes, particularly off-label use.
Regulatory Status
- FDA Approval: Approved under NDA 18-627.
- WHO prequalification: Not yet prequalified, limiting global procurement via UN agencies.
- Patent status: Expired in the US since 1991.
Pricing Trends and Projection
Current Pricing
- Retail prices in the US range between $3 to $7 per 50 mg capsule (excluding insurance or institutional discounts).
- Generic competition has driven prices down from high single-digit dollars to current ranges.
Historical Pricing
| Year |
Price per 50 mg Capsule |
Notes |
| 2010 |
~$8 |
Brand dominance, limited generics |
| 2020 |
~$5 |
Increased generics, pricing pressure |
| 2022 |
~$4.50 |
Continued generic penetration |
Projection: 2023-2027
- Prices are expected to stabilize or decline slightly due to increased generic competition.
- In regions with high endemic burden (India, Africa), prices could drop below $1 per capsule due to intense price competition.
- For markets requiring regulatory importation or centralized procurement (e.g., US government agencies), prices may hover around $2 to $4 per capsule.
Factors Influencing Price Trends
- Patent expiration and generic manufacturing.
- Global demand shifts, particularly in MDR-TB management.
- Procurement policies and funding in endemic regions.
- WHO prequalification status, which can influence international purchasing and pricing.
Competitive Landscape
- Major producers: Nichermed, Dr. Reddy’s Laboratories, and generic manufacturers in India and China.
- Biosimilar or alternative compounds are not available, maintaining Clofazimine’s position in niche markets.
- Off-label use limitations restrict broader demand outside specialized units.
Regulatory Outlook and Impact
- Potential US and EU expansion hinges on additional indications approval.
- WHO prequalification could increase volume sales, potentially lowering unit prices but expanding access.
Risks and Opportunities
Risks
- Decreased demand due to improved leprosy control programs.
- Regulatory barriers in non-endemic markets.
- Production capacity constraints if demand spikes unexpectedly.
Opportunities
- Expanding off-label use for MDR-TB could sustain or raise demand.
- Strategic stockpiling by global health organizations.
- Potential new indications under clinical development.
Key Takeaways
- The global market volume for NDC 00054-3553 is small and niche-specific, centered on leprosy and off-label MDR-TB applications.
- Pricing has decreased over recent years due to generic competition; further reductions are expected in endemic regions.
- The lack of patent protection and global health programs support continued low-cost access, with price projections trending downward in low-income markets.
- Regulatory developments and WHO prequalification could create sales opportunities but may not substantially alter current pricing trends.
FAQs
Q1: Is there potential for price increases due to new indications?
A1: Unlikely without regulatory approval for expanded indications, which could eventually drive demand and prices but currently remain uncertain.
Q2: How does patent status affect future pricing?
A2: Patent expiration has facilitated generic competition, driving prices downward. No patent protection remains, limiting pricing power.
Q3: Which regions offer the largest market for Clofazimine?
A3: India, Brazil, and Indonesia account for the majority of demand due to endemic leprosy; demand outside these regions is limited and mainly off-label.
Q4: How do supply chain risks impact pricing?
A4: Supply disruptions could cause temporary price spikes, but existing generic capacity minimizes long-term supply risk.
Q5: Can international health organizations influence pricing?
A5: Yes. WHO prequalification and bulk procurement agreements can lead to reduced prices but depend on global health policies and funding.
Citations
[1] WHO. Global Leprosy Report 2022.
[2] FDA. NDA 18-627 for Clofazimine.
[3] IQVIA. National Prescription Data, 2022.
[4] Market Imaging. Generic Drug Pricing Report 2022.
[5] Globally Endemic Leprosy Data, WHO, 2022.
